Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKPositive Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
SRPTNegative Net Change ADMAPositive Net Change ATRANegative Net Change ARGXNegative Net Change
biotechs
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRPositive Net Change EXELPositive Net Change SRPTNegative Net Change COLLNegative Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTNegative Net Change ARGXNegative Net Change OCGNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYPositive Net Change JNJPositive Net Change ABBVNegative Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
SRPTNegative Net Change PBYINegative Net Change ATRANegative Net Change ARGXNegative Net Change
biotechs
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDPositive Net Change ANIPPositive Net Change SAGENegative Net Change
biotechs medical pharmaceuticals
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
GILDNegative Net Change ANIPPositive Net Change ADMAPositive Net Change XLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKPositive Net Change SRPTNegative Net Change FUSNNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
BIIBPositive Net Change BMYPositive Net Change VRTXPositive Net Change INCYNegative Net Change
biotechnology biotechs
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
BIIBPositive Net Change BMYPositive Net Change VRTXPositive Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
SNYNegative Net Change AZNPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals vaccines
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
BMRNNegative Net Change LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechs earnings
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
BMYPositive Net Change PFENegative Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
REGNPositive Net Change SRPTNegative Net Change NTLAPositive Net Change ARGXNegative Net Change
biotechs
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
ALNYNegative Net Change SRPTNegative Net Change ZTSPositive Net Change BLUEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
JNJPositive Net Change SRPTNegative Net Change VNDANegative Net Change CTMXNegative Net Change
biotechs
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
by Zacks Equity Research
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
BIIBPositive Net Change ANIPPositive Net Change ADMAPositive Net Change SAGENegative Net Change
biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
by Ahan Chakraborty
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
SNYNegative Net Change BMYPositive Net Change MRKPositive Net Change GILDNegative Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
REGNPositive Net Change RHHBYPositive Net Change LLYNegative Net Change BAYRYPositive Net Change
biotechs medical pharmaceuticals
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSKPositive Net Change SRPTNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals vaccines
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BMRNNegative Net Change
biotechs medical
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYNegative Net Change SRPTNegative Net Change CTMXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
NVSPositive Net Change RHHBYPositive Net Change MORNegative Net Change ARVNNegative Net Change
biotechs earnings medical pharmaceuticals
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
VRTXPositive Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals